Real-world evaluation of 2023-2024 XBB.1.5 mRNA and protein-based COVID-19 vaccine reactogenicity from the randomized BEEHIVE trial.
Novavax's COVID vaccine triggered fewer side effects than Pfizer's in real-world 2023-2024 use.
This randomized controlled trial examined Real-world evaluation of 2023-2024 XBB15 mRNA and protein-based COVID-19 vaccine reactogenicity from the randomized BEEHIVE trial. The PubMed abstract reports There were significant differences in reactogenicity profiles for the 2023-2024 formulations of the NVX and PFZ COVID-19 vaccines, with NVX consistently associated with lower reactogenicity rates than PFZ.
What the study was
- Study design
- Randomized controlled trial
- Population
- Human participants or patients described in the abstract
- Sample size
- 453
- Category
- Other
- Maturity
- Validated
- Journal
- Human vaccines & immunotherapeutics
Why it surfaced
Randomized controlled trial with human evidence; score reflects novelty, clinical relevance, design quality, and population or unmet-need value under the v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.